Tumor Microenvironment & Cancer Treatment
- The complex interplay between immune cells and tumor cells within the tumor microenvironment (TME) dictates cancer progression and therapeutic success.
- Judith A.Varner, of the University of California San Diego, noted the complexity of the TME, explaining that macrophages, regulatory B-cells, regulatory T-cells (Tregs), and collagen-producing fibroblasts can stimulate...
- Macrophages, abundant in the TME, are categorized into M1 (antitumoral) and M2 (tumor-associated) subgroups.
Uncover the cutting-edge advances in immunotherapy targeting the tumor microenvironment—the key to unlocking new cancer treatment avenues.Recent findings presented at the 2025 ASCO Annual meeting spotlight how the TME, encompassing macrophages, fibroblasts, and immune cells, influences cancer progression and immunotherapy efficacy.Crucially, researchers are exploring innovative strategies, including harnessing JAK and LAG3 inhibitors, to enhance T-cell function—effectively turning “sprinters” into “marathon runners” for more durable responses.This could revolutionize how we approach cancer treatment. news Directory 3 reports on studies showing a 67% overall response rate using JAK inhibitors paired with pembrolizumab, a major step forward for patients. Discover what’s next for this rapidly evolving field and the potential for improved patient outcomes.
Immunotherapy Advances Target Tumor Microenvironment, Enhance T-Cell Function
Updated June 2, 2025
The complex interplay between immune cells and tumor cells within the tumor microenvironment (TME) dictates cancer progression and therapeutic success. Recent research presented at the 2025 ASCO Annual meeting underscored the dual role of the immune system, revealing how pro-tumor and anti-tumor forces within the TME impact immunotherapy responses.
Judith A.Varner, of the University of California San Diego, noted the complexity of the TME, explaining that macrophages, regulatory B-cells, regulatory T-cells (Tregs), and collagen-producing fibroblasts can stimulate tumor growth and metastasis.
Macrophages, abundant in the TME, are categorized into M1 (antitumoral) and M2 (tumor-associated) subgroups. Varner said macrophages typically exist in the M2 state, suppressing T-cell function and hindering their ability to attack tumor cells.
Macrophages also create physical barriers, preventing T-cells from reaching tumors. Fibroblasts, aided by macrophages, produce collagen, forming a dense network that blocks T-cell infiltration. Regulatory B cells and Tregs further contribute to immune suppression, protecting tumor cells from immune responses.
Conversely,CD8+ T cells,effector cytolytic T-cells,and natural killer (NK) cells directly combat tumor cells through cytotoxic mechanisms. Pro-inflammatory M1 macrophages and activated dendritic cells also play crucial roles in attracting immune cells and initiating targeted immune responses.
Interferons, cytokines released during infections, exhibit context-dependent effects within the TME. Andy J. Minn, of the University of Pennsylvania, explained that aberrant nucleic acids can trigger interferon production, activating Janus kinase (JAK) signaling and interferon-stimulated genes (ISGs).
Some ISGs enhance immune activation, while others promote immune evasion, mimicking chronic viral infections. minn said cancer cells exposed to chronic interferon levels undergo epigenetic reprogramming, similar to inflammatory memory.
Researchers are exploring JAK inhibitors, such as itacitinib, to block chronic interferon signaling and improve immunotherapy responses. In a study combining itacitinib with pembrolizumab for non-small cell lung cancer, researchers observed a 67% overall response rate and improved survival. The JAK inhibitor appeared to reset T-cell differentiation, preventing exhaustion.
Other strategies to enhance T-cell function involve LAG3 inhibitors. Dario Vignali, of the University of Pittsburgh, said that combining PD-1 and LAG3 blockade leads to enhanced T-cell signaling and partial reversal of exhaustion, resulting in more durable responses.
“Our data suggested that PD-1 generates sprinters that function effectively in a short period of time,perhaps [without] the durability required for a long-term fight against cancer,whereas this PD-1 LAG3 combination produced marathon runners that had durability,giving rise to increased efficacy over time,” said Vignali.
What’s next
ongoing research into the TME aims to refine cancer immunotherapy approaches, with the goal of manipulating the immune microenvironment to overcome resistance and improve treatment outcomes.